Valneva (NASDAQ:VALN) Sees Unusually-High Trading Volume

Valneva SE (NASDAQ:VALN) saw unusually-high trading volume on Thursday . Approximately 14,333 shares were traded during trading, an increase of 34% from the previous session’s volume of 10,711 shares.The stock last traded at $7.37 and had previously closed at $7.57.

Wall Street Analyst Weigh In

VALN has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $26.00 target price on shares of Valneva in a research note on Thursday, March 21st. Guggenheim reduced their price objective on shares of Valneva from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, March 22nd.

Valneva Stock Performance

The business has a fifty day moving average of $7.64 and a 200-day moving average of $9.41. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.37 and a current ratio of 1.65.

Valneva (NASDAQ:VALN) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.70). Valneva had a negative return on equity of 59.48% and a negative net margin of 65.99%. The firm had revenue of $45.12 million during the quarter, compared to analysts’ expectations of $45.06 million. As a group, research analysts expect that Valneva SE will post 0.11 EPS for the current year.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.